Two years ago, the Financial Accounting Standards Board was said to be "moving quickly" on a proposal that would call for listing employee stock options as expenses like any other among the company's profits and losses, rather than in footnotes as a pro-forma expense. (BioWorld Financial Watch)

If there is a textbook formula for when to conduct a public offering, Pharmion Corp. might have followed it to the letter on Thursday, raising $220.8 million just six weeks after receiving FDA approval for Vidaza. (BioWorld Today)